Trial Profile
Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Cystinuria
- Focus Therapeutic Use
- Acronyms TCUPS
- 16 Jul 2020 Results published in the Urology
- 20 Jan 2019 Status changed from recruiting to completed.
- 01 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2019.